Influence of Growth Hormone on a New Marker of Cartilage Metabolism (Chondrex) |
| |
Authors: | G Radetti M Bozzola V Braga C Paganini C Moretti S Adami |
| |
Institution: | (1) Department of Paediatrics, Regional Hospital of Bolzano, via L Boehler n° 5, 39100 Bolzano, Italy, IT;(2) Department of Paediatrics, Pavia, Italy, IT;(3) Rheumatologic Department, Ospedale di Valeggio, Italy, IT |
| |
Abstract: | The aim of this study was to evaluate the usefulness of a major secretory protein of human chondrocytes (chondrex) as a potential serum marker
of bone responsiveness to growth hormone (GH). The study included 18 children (10 F, 8 M), aged 10.9 ± 2.3 years, bone age
8.8 ± 2.7 years, height −2.3 ± 0.22 SDS, affected by isolated idiopathic GH deficiency (GHD). Serum samples for evaluation
of chondrex, total, and bone alkaline phosphatase were taken before and 3 and 6 months following treatment with rhGH. The
basal serum level of chondrex did not differ between patients (37 ± 22 ng/ml) and controls (33 ± 9.8 ng/ml). Following 6 months
of treatment with rhGH, a significant increase of height velocity SDS (from −2.8 ± 0.5 to 1.3 ± 0.7), total (from 195 ± 47
to 264 ± 79 U/liter) and bone alkaline phosphatase (from 81 ± 21 to 108 ± 30 U/liter) was observed, while chondrex serum level
remained unchanged (from 37 ± 22 to 36 ± 29 ng/ml). It was concluded that chondrex cannot be considered a reliable marker
of bone responsiveness to GH in the growing child.
Received: 19 March 1999 / Accepted: 3 February 2000 |
| |
Keywords: | : Growth hormone — Growth — Chondrex — XKL-40 |
本文献已被 PubMed SpringerLink 等数据库收录! |
|